“Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma” has been added to your cart. View cart

Article: Evaluation of the chromogenic dosage of FXII and its application to angioedema type III

€3.03

SKU: product-article-19757 Category: General

Description
Reviews (0)

Description

Evaluation of the chromogenic dosage of FXII and its application to angioedema type III

Reviews

There are no reviews yet.

Be the first to review “Article: Evaluation of the chromogenic dosage of FXII and its application to angioedema type III”

You must be logged in to post a review.

Top

Article: Evaluation of the chromogenic dosage of FXII and its application to angioedema type III

Description

Reviews

Related products

Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer

Article: Highlights in urologic cancer

Article: INTRODUCTION

1 year access Online Belgian Journal of Hematology (BJH)